Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1467335 in Healthy Male and Female Subjects (Double-blind, Randomised, Placebo-controlled Within Dose Groups)
Phase of Trial: Phase I
Latest Information Update: 27 Jul 2017
At a glance
- Drugs BI 1467335 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 21 Jul 2017 Status changed from active, no longer recruiting to completed.
- 13 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 11 Jan 2017 Planned End Date changed from 1 Apr 2017 to 1 Jul 2017.